Pharmacist interventions prevent drug-related problems in cancer chemotherapy
The introduction of clinical pharmacy services has led to improved therapy effectiveness and fewer adverse effects and unclear/compliant problems in cancer chemotherapy, a study has shown. Moreover, oncologists and patients highly acknowledge these pharmacist interventions, indicating a need to implement clinical pharmacy services in alternative hospitals.
A total of 102 patients treated with at least two cycles of any cancer type and stage were included in the analysis. Of these, 55 (53.9 percent) had 251 drug-related problems, which primarily involved antihypertensive (31.6 percent), antidiabetic (17.8 percent) and herbal agents (31.6 percent). The most common type of drug-related problems was treatment effectiveness (50.2 percent), followed by treatment safety (29.1 percent).
All 211 pharmacist interventions (110 percent) were accepted and deemed clinically relevant. At the prescriber level, the most common type of intervention was prescriber informed only. Of the identified drug-related problems, 86.4 percent were solved, 9.8 percent were partially solved, and 2.3 percent were unsolved.
“Clinical pharmacists have important roles in implementing scientifically valid knowledge and advice on safe, reasonable use of pharmaceuticals,” the authors said.
This prospective interventional study conducted from November 2017 to March 2018 used the Pharmaceutical Care Network Europe drug-related problem classification tool v8.01 to classify drug-related problems. The main outcome measure was the proposed interventions, which sought to identify drug-related problems, the role of the pharmacists in the resolution and the rate of acceptance of these recommendations by physicians.
“Clinical pharmacy services were introduced and evaluated in oncology clinic in a tertiary university hospital,” the authors said.